Annual Reports



  • 6-K (Feb 26, 2018)
  • 6-K (Feb 14, 2018)
  • SC 13G (Feb 8, 2018)
  • 6-K (Feb 1, 2018)
  • 6-K (Nov 13, 2017)
  • 6-K (Oct 30, 2017)
Kyocera 6-K 2016

Documents found in this filing:

  1. 6-K
  2. 6-K
Form 6-K
Table of Contents




Washington, D. C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of August 2016

Commission File Number: 1-07952


6 Takeda Tobadono-cho, Fushimi-ku,

Kyoto 612-8501, Japan

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  x        Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Registration S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Registration S-T Rule 101(b)(7):  ¨

Table of Contents


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.




Shoichi Aoki
Managing Executive Officer and
General Manager of
Corporate Financial and Accounting Group

Date: August 26, 2016

Table of Contents

Information furnished on this form:



1. Notice Relating to Merger of Kyocera Medical Corporation

Table of Contents

August 26, 2016

To All Persons Concerned,


Name of Company:    Kyocera Corporation
Name of Representative:    Goro Yamaguchi, President and Director
   (Code number: 6971, The First Section of the Tokyo Stock Exchange)
Person for Inquiry:   

Shoichi Aoki

Director, Managing Executive Officer and General Manager of Corporate Financial and Accounting Group

(Tel: +81-75-604-3500)

Notice Relating to Merger of Kyocera Medical Corporation

Kyocera Corporation (the “Company”), at a meeting of its Board of Directors held on August 26, 2016, resolved that the Company will merge Kyocera Medical Corporation (“Kyocera Medical”), a wholly owned consolidated subsidiary of the Company, effective as of April 1, 2017.

The above merger constitutes simplified merger and, accordingly, certain parts of the disclosure are omitted.


1. Purpose of Merger

Kyocera Medical is Kyocera Group’s principal subsidiary in the medical and health care market, one of the Group’s important markets. It develops products such as artificial joints, artificial bones and dental implants, taking advantage of the highly biocompatible characteristics of fine ceramics and titanium alloy. The Company believes that expansion of business in this market going forward will increasingly require long-term joint study with research and development institutions and cultivation of new business areas. The purpose of the contemplated merger is to pursue new business opportunities based on the medical materials technologies fostered by Kyocera Medical, and to achieve synergies with the Company’s brand and the Company’s rich management resources.


2. Outline of Merger


(1) Schedule of merger

Meeting of Board of Directors of Kyocera Medical to approve merger agreement

   August 26, 2016

Meeting of Board of Directors of the Company to approve merger agreement

   August 26, 2016

Execution of merger agreement

   August 31, 2016 (Scheduled)

(Note)  Each of the Company and Kyocera Medical will undertake this merger without approval of a general shareholders’ meeting pursuant to Article 796, paragraph 2 of the Companies Act (simplified merger) (in the case of the Company) and Article 784, paragraph 1 of the Companies Act (short form merger) (in the case of Kyocera Medical).

Effective date of merger

   April 1, 2017 (Scheduled)

Application for registration of merger in the commercial register

   April 3, 2017 (Scheduled)



Table of Contents
(2) Method of merger

In the merger, the Company will be the surviving company, and Kyocera Medical will be dissolved.


(3) Merger ratio and delivery of cash due to mergers

The merger is between the Company and a wholly owned subsidiary thereof, and, accordingly, no new shares will be issued and no cash due to merger shall be delivered.


(4) Treatment of warrants and bonds with warrants in merger



(5) Outlines of parties to the merger (as of March 31, 2016)



Surviving Company


Dissolving Company

1) Name

  Kyocera Corporation   Kyocera Medical Corporation

2) Principal Office


6 Takeda Tobadono-cho,

Fushimi-ku, Kyoto, Japan


3-3-31 Miyahara, Yodogawa-ku,

Osaka, Japan

3) Name and Title of Representatives


Goro Yamaguchi

President and Director


Yoshio Kojima

President and Director

4) Principal Businesses


Fine ceramic parts business

Semiconductor parts business

Applied ceramic products business

Electronic device business

Telecommunications equipment business, etc.


Design, development,

manufacture and sales of medical

equipment and businesses as a total

medical materials manufacturer

5) Capital Amount

  115,703 million yen   2,500 million yen

6) Date of Incorporation

  April 1, 1959   September 1, 2004

7) Number of Shares Issued and Outstanding



(of which 10,761,503 shares are treasury stock)



(there is no treasury stock)

8) Fiscal Year End

  March 31   March 31

9) Major Shareholders and Their Share Ownership Ratios


•  The Master Trust Bank of Japan, Ltd. (Trust Account) 9.91%

•  Japan Trustee Services Bank, Ltd. (Trust Account) 6.61%

•  State Street Bank and Trust Company 5.16%

•  The Bank of Kyoto, Ltd. 3.94%

•  Kazuo Inamori 3.06%

(Shareholding ratios are calculated after deduction of treasury shares)

  Kyocera Corporation 100%



Table of Contents
(6) Performance and financial condition for most recent fiscal year (year ended March 31, 2016)

(Millions of Yen)



Kyocera Corporation


Kyocera Medical Corporation

Total Equity

  1,890,882   15,222

Total Assets

  2,390,223   18,556

Total Equity per Share (yen)

  5,154.27   304,437.88

Net Sales

  592,979   15,865

Profit from Operations

  28,147   1,502

Recurring Profit

  94,598   1,561

Net Income

  74,041   1,009

Net Income per Share (yen)

  201.82   20,175.70


(7) Company following the merger

There will be no change in the trade name, business, location of headquarters, representative directors, capital amount or fiscal year end of the Company as a result of the merger.


(8) Forecasts

Because this merger is between the Company and its wholly owned subsidiary, and the effective date of the merger is scheduled to be April 1, 2017, the merger will have no impact on the financial forecast of the Company for the fiscal year ending March 31, 2017.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki